Office of Licensing & Ventures

About OLV

News

Read the latest announcements coming from OLV. Click a headline for details.

Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
May 9, 2013
Forest Laboratories leads Trevena's $60 Million Series C Funding Round; All existing investors to also participate

Trevena to present first-in-man study results for mu-opioid biased ligand TRV130
March 18, 2013
Poster at the 2013 AAN meeting describes the human safety and
pharmacology of intravenous analgesic TRV130 in healthy volunteers.

Trevena GPCR platform yields a novel mu-opioid biased ligand analgesic with side effect benefits
January 23, 2013
JPET publication describes the discovery and activity of TRV130

Regado Biosciences, Inc. Secures $51 Million Series E Financing
December 17, 2012
New Investor Leads Round to Fund Phase 3 Development of REG1

Precision BioSciences Announces Publication of Cotton Trait Stacking Success in Collaboration with Bayer CropScience
November 26, 2012
Herbicide Tolerance Gene Precisely Inserted Adjacent to Insect Resistance Gene using Site-Specific Genome Editing Technology

Trevena Completes FTIH Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain
November 14, 2012
TRV130 is generally well-tolerated and rapidly enters the CNS in healthy adult males.

Celsion Announces Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer Reaches Target Number of Events for Unblinding
November 9, 2012
Company Begins Data Collection, Expects to Report Top Line Data in January 2013; Reiterates Strong Balance Sheet Position

Faster decisions at the cutting edge
October 15, 2012
Cambridge Consultants partners with HemoSonics on diagnostic instrument development for blood clotting disorders

Trevena, Inc. Founder Wins Nobel Chemistry Prize
October 10, 2012
The 2012 Nobel Prize for Chemistry has been awarded to Robert Lefkowitz and Brian Kobilka for their work on the G-protein coupled receptor system and its application in medical science.

Trevena Completes Phase 2a Study of TRV027 in Patients with Advanced Heart Failure
October 8, 2012
TRV027 improves hemodynamics and is well-tolerated in patients with stable advanced heart failure, supporting advancement into a Phase 2b study in ADHF

GrassRoots Biotechnology and Monsanto extend research collaboration
September 27, 2011
GrassRoots Biotechnology and Monsanto extend research collaboration

Celsion Announces Issuance of U.S. Patent Covering ThermoDox(R) Technologies
April 13, 2011
New Patent Extends U.S. Intellectual Property Protection of ThermoDox(R) and Other Temperature-Sensitive Liposomal Formulations to 2021

Page of 4 Next 20 »